Jaheeda Gangannagaripalli

Jaheeda Gangannagaripalli

Auto-generated profile, based on publicly available information

Jaheeda Gangannagaripalli

The University of Manchester Faculty of Biology Medicine and Health, Manchester, UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2021 in Journal of Patient Safety
Verified
Journal Article
Closed access
LMLuke Mounce
Luke Mounce
NSNde-Eshimuni Salema
Nde-Eshimuni Salema
JGJaheeda Gangannagaripalli
Jaheeda Gangannagaripalli
IRIgnacio Ricci-Cabello
Ignacio Ricci-Cabello
AAAnthony J. Avery
Anthony J. Avery
JVJose M. Valderas
Jose M. Valderas
Objectives: The Patient Reported Experiences and Outcomes of Safety in Primary Care (PREOS-PC) is a valid and reliable instrument (61 items across 5 domains) of patients’ perceptions of safety. Stakeholder feedback has supported shorter versions for improving choice and facilitating uptake of routine patient-centered evaluation. We sought to develop 2 shorter versions of PREOS-PC: one including the shortest possible scales that met established measurement performance standards and a screening version including a single item per domain. Methods: A total of 1244 patients from 45 general practices across England completed PREOS-PC questionnaires. All scale items in PREOS-PC underwent Item Response Theory analysis, applying standard criteria for the item reduction. Cognitive debriefing from 10 patient interviews allowed for the assessment of the instruments’ readability. The instruments’ psychometrics properties were reassessed in a validation sample of 1557 patients in 21 English general practices. Results: “PREOS-PC Compact” includes 25 items and 2 open-ended questions across the 5 domains, 44% of the length of the original instrument. “PREOS-PC Screen” consists of 6 items: the best-performing single items for 2 domains, 1 item modified from original items for each of the remaining 3 domains, and 1 open-ended question. The evaluation of the instruments confirmed they were acceptable to patients and met standards for readability; construct, convergent, and divergent validity; and reliability. Conclusions: PREOS-PC Compact meets high-performance standards while reducing patient burden for routine monitoring of patient safety in primary care. PREOS-PC Screen is a concise tool apt for incorporation into audits and to target more in-depth review as needed.

12 May 2025 in British Journal of General Practice
Verified
Journal Article
Open access
PDF file
YPYan Pang
Yan Pang
ASAnna Szücs
Anna Szücs
IRIgnacio Ricci-Cabello
Ignacio Ricci-Cabello
JGJaheeda Gangannagaripalli
Jaheeda Gangannagaripalli
LGLay Hoon Goh
Lay Hoon Goh
JVJose M. Valderas
Jose M. Valderas
Background: Engaging patients and families has been promoted as a key strategy for improving patient safety of health systems. However, evidence remains scarce on the effectiveness of this approach in primary care. Aim: To assess the combined effectiveness of primary care interventions in randomised controlled trials (RCTs) promoting patient and family engagement in patient safety. Design and setting: A systematic review and meta-analysis. Method: The review followed PRISMA and Cochrane guidelines. Five electronic databases (Medline, CINAHL, Embase, Web of Science, CENTRAL) were searched from inception to 18 September 2024 with keywords in four blocks (patient and family engagement; patient safety; primary care; randomised controlled trial). Patient and family engagement levels were appraised. Where appropriate, results were combined into meta-analyses. Results: Of the 19 included records, 12 reported on completed RCTs. Only one intervention integrated patients/families into overall care safety (high engagement); six aimed at enhancing skills and tools (intermediate), and 12 informed patients/families how to engage and prompted them to do it (low). RCTs primarily targeted medication safety, with meta-analyses showing no significant effects on reducing adverse drug events (odds ratio [OR] 0.86, 95% confidence interval [CI] = 0.70 to 1.08) or improving medication appropriateness measured categorically (OR 0.92, 95% CI = 0.76 to 1.13) or continuously (mean difference 0.71, 95% CI = −0.10 to 1.52). Overall risk of bias was low and certainty of evidence very low to moderate. Conclusion: Existing randomised controlled evidence on patient and family engagement in primary care remains inconclusive and limited in scope. Future interventions should include higher levels of engagement and address more diverse patient safety outcomes relevant for primary care.

1 November 2021 in Health Services and Delivery Research
Verified
Journal Article
Closed access
PDF file
JGJaheeda Gangannagaripalli
Jaheeda Gangannagaripalli
IPIan Porter
Ian Porter
ADAntoinette Davey
Antoinette Davey
IRIgnacio Ricci-Cabello
Ignacio Ricci-Cabello
JGJoanne Greenhalgh
Joanne Greenhalgh
JVJose M. Valderas
Jose M. Valderas
Background: Drug-related problems and potentially inappropriate prescribing impose a huge burden on patients and the health-care system. The most widely used tools for appropriate prescription in older adults in England and in other European countries are the Screening Tool of Older People’s Prescriptions (STOPP)/Screening Tool to Alert to the Right Treatment (START) tools. STOPP/START tools support medicines optimisation for older adults.Objectives: To identify, test and refine the programme theories underlying how interventions based on the STOPP/START tools are intended to work, for whom, in what circumstances and why, as well as the resource use and cost requirements or impacts.Design: A realist synthesis.Setting: Primary care, hospital care and nursing homes.Patients: Patients aged ≥ 65 years.Interventions: Any intervention based on the use of the STOPP/START tools.Review methods: Database and web-searching was carried out to retrieve relevant evidence to identify and test programme theories about how interventions based on the use of the STOPP/START tools work. A project reference group made up of health-care professionals, NHS decision-makers, older people, carers and members of the public was set up. In phase 1 we identified programme theories about STOPP/START interventions on how, for whom, in what contexts and why they are intended to work. We searched the peer-reviewed and grey literature to identify documents relevant to the research questions. We interviewed experts in the field in our reference group to gain input on our list of candidate context–mechanism–outcome configurations, to identify additional context–mechanism–outcome configurations and to identify additional literature and/or relevant concepts. In phase 2 we reviewed and synthesised relevant published and unpublished empirical evidence and tested the programme theories using evidence from a larger set of empirical studies.Results: We developed a single logic model structured around three key mechanisms: (1) personalisation, (2) systematisation and (3) evidence implementation. Personalisation: STOPP/START-based interventions are based on shared decision-making, taking into account patient preferences, experiences and expectations (mechanisms), leading to increased patient awareness, adherence, satisfaction, empowerment and quality of life (outcomes). Systematisation: STOPP/START tools provide a standardised/systematic approach for medication reviews (mechanisms), leading to changes in professional and organisational culture and burden/costs (outcomes). Evidence implementation: delivery of STOPP/START-based interventions is based on the implementation of best evidence (mechanisms), reducing adverse outcomes through appropriate prescribing/deprescribing (outcomes). For theory testing, we identified 40 studies of the impact of STOPP/START-based interventions in hospital settings, nursing homes, primary care and community pharmacies. Most of the interventions used multiple mechanisms. We found support for the impact of the personalisation and evidence implementation mechanisms on selected outcome variables, but similar impact was achieved by interventions not relying on these mechanisms. We also observed that the impact of interventions was linked to the proximity of the selected outcomes to the intervention in the logic model, resulting in a clearer benefit for appropriateness of prescribing, adverse drug events and prescription costs.Limitations: None of the available studies had been explicitly designed for evaluating underlying causal mechanisms, and qualitative information was sparse.Conclusions: No particular configuration of the interventions is associated with a greater likelihood of improved outcomes in given settings.Study registration: This study is registered as PROSPERO CRD42018110795.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Services and Delivery Research programme and will be published in full inHealth Services and Delivery Research; Vol. 9, No. 23. See the NIHR Journals Library website for further project information.

16 August 2018 in Shoulder & Elbow
Verified
Journal Article
Open access
JEJonathan P Evans
Jonathan P Evans
CSChris Smith
Chris Smith
IPIan Porter
Ian Porter
JGJaheeda Gangannagaripalli
Jaheeda Gangannagaripalli
VGVictoria A Goodwin
Victoria A Goodwin
JVJose M. Valderas
Jose M. Valderas
Background: For Patient-Reported Outcome Measures to be useful, they must have evidenced reliability, validity and responsiveness in both the condition and population of interest. The aim of this study is to systematically review the evidence for Patient-Reported Outcome Measures in UK patients with lateral elbow tendinopathy. Methods: A systematic search was performed in Ovid MEDLINE, Embase and CINAHL. Studies were included if reporting administration of Patient-Reported Outcome Measures in UK populations with lateral elbow tendinopathy. Patient-Reported Outcome Measures characteristics and target populations were assessed using a structured classification system. Patient-Reported Outcome Measures reporting in randomised controlled trials was assessed against Consolidated Standards of Reporting Trials (CONSORT) standards (Patient-Reported Outcome extension). Results: A total of 16 articles were included. Out of seven different Patient-Reported Outcome Measures, there was evidence of partial validation for five. The assessment of validity, reliability and responsiveness of all Patient-Reported Outcome Measures in lateral elbow tendinopathy UK populations extended to just 20 individual patients. No articles conformed to the CONSORT Patient-Reported Outcome extension standards. Conclusion: There exists a paucity of data on the psychometrics of Patient-Reported Outcome Measures in UK lateral elbow tendinopathy populations. Without these data, trial design and interpretation are significantly hindered. The high prevalence of this condition and significant volume of studies being conducted into novel treatments highlight the need for this knowledge gap to be resolved.

19 August 2025 in BMJ Open
Verified
Journal Article
Open access
PDF file
JGJaheeda Gangannagaripalli
Jaheeda Gangannagaripalli
EVEmma Vardy
Emma Vardy
ESEmma Stanmore
Emma Stanmore
Introduction Around 885 000 people live with dementia in the UK, of whom around 50% experience a fall each year. ‘Keep On Keep Up’ (KOKU) is a National Health Service-approved gamified, digital health programme designed to maintain function and reduce falls through strength and balance exercises (Fitness and Mobility Exercise/OTAGO Exercise Programme (OTAGO)), and health literacy games. KOKU has been adapted to the needs of people living with dementia in the community (known as KOKU-LITE). This trial aims to test the feasibility and acceptability of trial processes and usability of KOKU-LITE. Methods and analysis A two-arm, parallel, non-blinded feasibility randomised controlled trial will be conducted using mixed methods. Participants aged ≥55 years with any type but varying levels of dementia from mild to moderate stages (ratings 1 and 2 on clinical dementia rating (CDR) scale) and meeting the eligibility criteria will be recruited from patient organisations across Greater Manchester, UK. The target sample size is 60 for the trial. Participants randomised into the intervention arm will use the KOKU-LITE programme for 30 min, 3 times a week for 6 weeks plus dementia-specific falls prevention leaflet and participants randomised into the control arm will receive dementia-specific falls prevention leaflet. Outcome measures: primary outcomes: recruitment, retention and adherence rates; secondary outcomes: quality of life, participants’ activities of daily living, physical activity levels, functional ability, lower limb strength, concerns about falling, falls risk, mood and user’s experience of the technology. Post-intervention interviews or focus groups with participants and health and social care professionals will explore the feasibility of trial processes and technology and evaluate the usability and acceptability of the intervention, respectively. Analyses will be descriptive. Trial status: the first participants were recruited on 20 March 2024. Data collection is currently ongoing. Ethics and dissemination This feasibility trial has been reviewed and received favourable ethical approval from Yorkshire & The Humber—Bradford Leeds Research Ethics Committee, Newcastle upon Tyne (REC reference 23/YH/0262). The findings of the study will be disseminated through peer-reviewed scientific journals, at conferences, publication on University of Manchester, Applied Research Collaboration Greater Manchester and KOKU websites. Trial registration number NCT06149702.

1 July 2026 in medRxiv
Verified
Preprint
Open access
BLBethany Linder
Bethany Linder
JDJiamin Du
Jiamin Du
NTNuno Tavares
Nuno Tavares
TZTingting Zhu
Tingting Zhu
Prayag TiwariPrayag Tiwari
Prayag Tiwari
JGJaheeda Gangannagaripalli
Jaheeda Gangannagaripalli
Background: Polypharmacy is common in people living with dementia (PLwD) and associated with adverse outcomes. Although Structured Medication Reviews (SMRs) are recommended to optimise medication regimens, their delivery is often constrained by limited healthcare resources. Artificial intelligence (AI) may support SMRs, yet little is known about how it is perceived by PLwD and their carers. This study explored their experiences of polypharmacy, views on SMRs, and attitudes towards use of AI tools in SMRs. Methods: Semi-structured interviews with 12 PLwD experiencing polypharmacy and two focus groups with 14 carers were conducted via Microsoft Teams or telephone and analysed using Reflexive Thematic Analysis. Results: Two themes were constructed: experiences of SMRs, and attitudes towards AI in SMRs. Participants described challenges in managing polypharmacy, with carers often playing a central role in supporting adherence and monitoring side effects. Experiences of SMRs varied widely. SMRs were most valued when clinicians were empathetic and able to offer personalised guidance. Participants viewed AI use in SMRs positively, provided that such tools were well validated and used to assist rather than replace healthcare professionals. AI was viewed as having the potential to reduce administrative burden and support more person-centred care. However, some had concerns regarding patient safety and data security, highlighting the need for appropriate regulation and human oversight. Conclusion: Participants were supportive of AI use in SMRs, despite concerns about safety, data security and disclosure of AI use, and emphasised the importance of patient–clinician interactions and lived experience involvement in AI tool development.